News

Latest updates on our clinical development programs and company milestones.

Celfex AB to engage Noah Therapeutics for Phase 2 Clinical Trial

July 25, 2025

Celfex AB is pleased to announce its engagement with Noah Therapeutics to conduct a Phase 2 clinical trial evaluating the safety and efficacy of its proprietary topical Fexofenadine formulation for the treatment of mild to moderate Atopic Dermatitis.

Celfex AB enters sub-license agreement with MHG

March 7, 2025

Celfex AB has entered into a sub-license agreement with MHG Management GmbH for the development and commercialization of topical Fexofenadine for Atopic Dermatitis. This agreement secures Celfex's rights to the intellectual property portfolio.